Insilico Medicine vs Recursion
Two listed companies running the same double business, platform vendor and clinical stage biotech at once, and the comparison comes down to how far each has got a molecule. Insilico has the cleaner end to end story: its target identification engine picked the target, its generative chemistry engine designed the molecule, the discovery was published in peer reviewed literature and the asset holds orphan drug designation. Recursion has the deeper data asset, generating its own biology at scale and learning from cellular images and multiomic data rather than from public sources, with disclosed partnership economics that show what pharmaceutical companies have actually paid. Both structures carry the same conflict: the company that chooses the target also designs the molecule, runs the analysis and reports the result. Judge both on assets that clear human trials, not on platform architecture.
- It is the clearest end to end case in the category: one engine prioritised the target, another generated the molecule, and the resulting drug reached the clinic, with the discovery published in peer reviewed literature.
- The regulatory position is real rather than prospective, with orphan drug designation held on a lead asset, which is the kind of external checkpoint this category rarely reaches.
- The platform is sold as software as well as run internally, with named engines and disclosed methods, so a pharmaceutical customer can license the same tools rather than only partner.
- The data flywheel is the asset: high throughput cellular experimentation feeding machine learning on imaging and multiomic data, so the platform generates its own training data rather than mining public sources.
- Partnership economics are disclosed as a listed registrant, so the market's valuation of the platform is visible rather than described in a press release.
- The oversight is empirical by construction, with model hypotheses tested in the wet laboratory before they advance.
Side by Side
| Axis | I Insilico Medicine |
R Recursion |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both companies are simultaneously platform vendors and clinical stage biotechs, which is the structural conflict worth understanding before reading any of their evidence: the same organisation selects the target, designs the molecule, runs the analysis and reports the result. Neither publishes a security attestation or trust centre. Insilico publishes extensively and still leaves the governance question unanswered, which are different things.
Recursion narrowed its internal pipeline in 2025, so any breadth claim predating that should be checked. Pipeline progress is the only evidence that ultimately matters in this category and both should be judged on assets that clear human trials rather than on platform descriptions.